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Background: The benefit to risk ratio of the treatment with erythropoietin (EPO) as a means of limiting the number
of transfusions in very preterm infants during hospitalization, seems to be modest since the adoption of restrictive
transfusion criteria and of policy limiting phlebotomy losses. We therefore aim to evaluate the factors associated
with the number of late blood transfusion in very preterm infants in a unit where the routine use of EPO has been
discontinued.
Methods: A comparative “before-after” study was carried out in premature infants born before 32 weeks
postmenstrual age (PMA), over a period of one year before (EPO group) and one year after (non-EPO group) the
discontinuation of EPO therapy.
Results: A total of 48 infants were included in the study (EPO=21; non-EPO=27). The number of infants transfused
after the 15 day of life (D15) and the number of transfusions per infant after D15 were not significantly different
between the two groups. In a multivariate analysis, the gestational age and the volume of blood drawn off during
the first month of life significantly influenced the need for transfusions after the 15th day of life, independently of
the treatment with EPO. The hemoglobin levels measured at different times of hospitalization (median postnatal
age: 16, 33 and 67 days) were not significantly different between the two groups.
Conclusions: Our study shows that the discontinuation of EPO did not change the number of late transfusions.
Even when a policy limiting phlebotomy losses is used, blood loss is an important and independent risk factor for
late transfusion of very preterm infants.
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The anemia of premature infants is more severe and
more prolonged than of term neonates. Below a certain
threshold, this anemia becomes pathologic as it no longer
permits a tissue oxygenation adequate for growth and
development, and then, a blood transfusion is required.
Since infants born prematurely display low erythropoietin
(EPO) plasma levels and a retarded increase in its secre-
tion, the use of recombinant EPO to limit the number of
transfusions in premature infants has been proposed since* Correspondence: alexandre.lapillonne@nck.aphp.fr
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reproduction in any medium, provided the ora pilot study published in the 90’s [1]. The controlled
randomized trials which were then published showed
that the use of EPO in premature neonates significantly
reduces the number of transfusions and the volume of
blood transfused [2-6]. These studies also highlighted
the facts that very broad and liberal transfusion criteria
were used [3] and that the quantities of blood drawn off
could be responsible of important blood losses [7]. The
studies published since 2000 indicate that the effects of
EPO treatment on the requirement for blood transfusions
are moderate if more strict transfusion criteria and policy
to limit phlebotomy losses are applied [8-12]. Furthermore,
they showed that EPO does not reduce the need forl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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account of the delayed action of the hormone [15].
In 2006, the Cochrane collaboration published three
meta-analyses [14,16,17]. The first showed that administra-
tion of EPO from the 8th day of life afforded a reduction in
the volume of blood transfused of 7 mL/kg/infant and a
diminution of 0.78 transfusions per infant. Conversely, the
use of EPO did not diminish the risk of transfusion as there
was no significant reduction in the number of donors [16].
The second indicated that EPO therapy started within the
first 7 days of life permitted a decrease in the volume of
blood transfused of 6 mL/kg/infant, a diminution of 0.33
transfusions per infant and a significant decrease in the
number of donors. This study revealed, on the other hand,
a significant increase in the incidence of retinopathy of
stage ≥3 [17]. Finally, the third meta-analysis showed that
the number of transfusions and the volume of blood
transfused were similar whether EPO was administered
early (before 8th day of life) or late [14]. Since these
successive analyses, more strict transfusion criteria have
been progressively adopted by neonatal intensive care
units (NICUs) in France and other countries, and the
indications for treatment with EPO have been progressively
restricted [18].
For about 10 years, we have implemented in our NICU a
policy of conservative blood management, and a protocol
including strict blood transfusion criteria. In view of the
above data showing a modest impact of EPO treatment
on transfusion requirements, together with the potentially
severe side effects [19] and the fact that the procedure
is painful for the infant [20], it was decided in our neonat-
ology unit to suspend EPO therapy in premature new-
borns as of 1st August 2010. The objective of the present
study was to evaluate the effects of this policy change on
late transfusion requirements (i.e., after 15 days of life;




A “before-after” study was carried out in the NICU of the
Territorial Hospital Center of French Polynesia during
two consecutive years before and after the discontinuation
of EPO therapy: from 01/08/2009 to 31/07/2010, i.e., one
year before the arrest of EPO treatment (treated group)
and from 01/08/2010 to 31/07/2011, i.e., one year after
the arrest of treatment (non-treated group). The data were
retrieved from the medical records.
Inclusion and exclusion criteria
All premature infants born at a postmenstrual age
(PMA) < 32 weeks and a birth weight ≤ 1500 g during
the study periods were included. The exclusion criteria
were infants suffering from a congenital malformation ora hemolytic disease (i.e., blood group incompatibilities and
G6PD or pyruvate kinase deficiencies), and those who had
required surgery.Patient care protocols
The infants belonging to the treated group received EPO
(Epoetin beta, NeoRecormon®, ROCHE, France) from the
first week of life (1st injection between D3 and D7), at a
dose of 250 IU/kg three times a week subcutaneously for
6 weeks, i.e., a total of 18 injections.
The service has a policy of conservative blood man-
agement and a single donor for a given patient. Blood
samples were drawn into tubes clearly indicating the
quantity of blood necessary or were capillary samples. The
quantity of blood required for blood cultures (0.5 mL) was
measured in a syringe before being injected into the blood
culture flask. Samples were analyzed by micro-methods
and these methods were not modified between the two
periods of the study. The samples were transferred rapidly
to the laboratory by means of a pneumatic tube system.
A limited number of physicians were responsible for the
prescription of biological tests: the clinician in charge of
the unit and the duty doctor. Particular attention was paid
to the frequency and grouping of the blood tests. Finally,
the unit protocol includes giving back the blood drawn on
an umbilical line before the actual blood sample is obtained.
Enteral feeding was introduced progressively and as a
function of the digestive tolerance. All infants were fed
with pasteurized human milk until they reach 32 weeks
corrected age, and then fed with either mother’s milk
enriched with a fortifier (Eoprotine®, MILUMEL, France) at
a final concentration of 3% or a preterm formula (Pregallia®,
DANONE, France). The feeding protocol was not modified
between the two periods of the study.
All the infants received an enteral iron supplement after
the 7th day of life as soon as the total enteral intake
reached ≥100 mL/kg/d. The initial dose was 1.4 mg/kg/d
and was increased stepwise by 1.4 mg/kg/d every 48 h, ac-
cording to the digestive tolerance, up to a target dose of 6.8
mg/kg/d (Sodium feredetate, Ferrostrane®, TEOFARMA,
Italy). All the infants of the study were likewise given a folic
acid supplement for one month, at a dose of 1.25 mg/d or-
ally, as soon as the enteral intake exceeded 100 mL/kg/d.
The protocol for iron and folic acid supplementation
underwent no modifications between the two periods of
the study.
The indications for transfusion were the following proto-
col throughout the 2 study periods: 1) hemoglobin <12 g/dL
if the infant was less than 48 h old, required respiratory
support with FiO2 ≥40% or presented pulmonary arterial
hypertension; 2) hemoglobin <9 g/dL in the case of
respiratory support with Fi02 <40%, poor weight gain,
episodes of hypoventilation, severe associated pathology
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ume of blood delivered in each transfusion was 15 mL/kg.
Data collection
The epidemiological, clinical and biological data for each
infant included were recovered from the medical records
by one person (O.B.). Intrauterine growth retardation
(IUGR) was defined as a birth weight of less than the
10th percentile for the gestational age on reference curves
[21]. The achievement of respiratory autonomy was defined
as spontaneous respiration in ambient air without tracheal
or nasal support. Postnatal steroid therapy was defined as
systemic therapy targeting the lungs and administered ≥15
days of life. Severe cerebral lesions were defined as intra-
ventricular hemorrhage (IVH) of a grade ≥3 of the Papile
classification [22] or as cystic periventricular leukomalacia.
The presence of retinopathy of any stage, of a nosocomial
infection suspected or confirmed by clinical, biological
or bacteriological data, or of necrotizing enterocolitis of
stage ≥3 of the Bell classification was likewise retrieved.
Hemoglobin levels were measured at different times of
hospitalization: during the first 24 hours of life (Hb at
day 0), between the 14th and 21st days of life (Hb at 2 to
3 wks), between the 28th and 42nd days of life (Hb at
1mo) and between the 6th week of life and discharge from
hospital or at the death of the infant (Hb at discharge).
The theoretical volume of blood drawn off for biological
tests during the first 30 days of life was noted and recorded
as a function of the birth weight.
The number of infants transfused and the number of
transfusions per infant were retrieved for the period
from the day of birth to discharge from hospital or death.
Owing to the geographic situation of the hospital, no
secondary transfers were performed. Transfusions were
categorized as early when they took place <15 days of life
and late ≥15 days of life.
Ethical information
This study was conducted according to the guidelines
of the Declaration of Helsinki. According to French
legislation, neither ethical approval nor informed consent
was required for this non-interventional, retrospective
cohort study.
Statistical analyses
Statistical analyses were performed using Minitab 13.3®
software (Minitab Inc., Pennsylvania, USA). Qualitative
variables were expressed as percentages and quantitative
variables as medians and extremes. The variables “gesta-
tional age at birth” and “birth weight” were divided into the
following classes: <28 weeks, 28–29.9 weeks and 30–32
weeks for the gestational age and <1000 g and ≥1000 g
for the birth weight. Discontinuous data were compared
with the Fisher exact test and continuous data with theMann–Whitney U test. To determine the factors that
affect the need for transfusion after the 15th day of life,
the factors presenting a degree of significance of p ≤ 0.1 in
the univariate analysis (i.e., intrauterine growth retard-
ation, gender, gestational age) were included in a binary
logistic regression model together with the volume of
phlebotomy losses and the treatment with EPO. The rela-
tions between these factors were expressed as odds ratio
with a 95% confidence interval. Tests were considered to
be significant for a p value of less than 0.05.
Results
Description of the study groups
All eligible infants (n=48) were included in the study: 21
in the treated group and 27 in the non-treated group.
None were excluded because of postnatal transfer since
the unit is geographically very far from any other level II
ou level III units (i.e., no other neonatal unit in the island
of Tahiti). The clinical characteristics of the children are
presented in Table 1. The two groups were comparable
for all criteria except gender (p=0.01), the incidence of
IUGR (p=0.04) and severe neurological lesions (p=0.02).
Two children died during the study on D43 and D54
respectively; both belonged to the treated group. The
hemoglobin at birth, the number of early transfusions and
the volume of blood drawn off during the first month of
life were comparable (Table 2).
Effects of the EPO treatment
The number of infants transfused after D15 was identical
in the two groups (Table 2). The number of transfusions
per infant after D15 (mean ± SD = 0.5 ± 0.9 in the treated
group and 0.4 ± 0.6 in the non-treated group) was not
significantly different nor was the volume of blood
transfusion of the transfused infants (mean ± SD = 23.6 ±
11.8 mL/kg in the treated group and 18.3 ± 6.6 mL/kg in
the non-treated group).
In the binary logistic regression model, only the variables
“gestational age” and “volume of phlebotomy losses” were
significantly and independently associated with the need
for transfusion after 15 days of life, whereas treatment
with EPO was not significant (Table 3). The levels of
hemoglobin at different times of hospitalization were not
significantly different between the two groups (Table 2).
Discussion
Our study shows that the discontinuation of EPO therapy
did not significantly modify the number of infants trans-
fused, the number of transfusions per infant after D15 or
the hemoglobin levels after the 15th day of life in infants
born very preterm. These results are concordant with those
of the literature, which indicate that the clinical effects of
EPO are limited or absent when restrictive transfusion cri-
teria are employed [8,9,12,23,24]. Our work also confirms
Table 1 Clinical characteristics of the newborns included in the study
Treated group (n= 21) Non treated group (n= 27) Total (n=48) p
Gender*
boy 14 (67 %) 8 (30 %) 22 (46 %) 0.01
Gestationnal age (week) ** 28.1 [26.1-31.8] 29.3 [25.6-31.8] 28.6 [25.6-31.8] 0.1
Birth weight (g) 1100 [802- 1428] 1110 [666- 1496] 1105 [666- 1496] 0.7
Birth length (cm) 36.5 [30.0- 40.8] 37 [31- 43] 37 [30- 43] 0.3
Birth head circumference (cm) 26.5 [22.0- 29.5] 26 [22.5- 28.5] 26 [22- 29.5] 0.4
Birth weight < 1000 g 7 (33 %) 8 (30 %) 15 (31 %) 0.8
Intrauterine growth retardation 3 (14 %) 11 (40 %) 14 (29 %) 0.04
Apgar score
1 mn 7 [2- 10] 6 [3- 10] 6.5 [2- 10] 0.3
5 mn 9 [5- 10] 9 [7- 10] 9 [5- 10] 0.3
10 mn 10 [8- 10] 10 [8- 10] 10 [8- 10] 0.9
Duration of hospitalization (d) 67 [40 - 102] 63.5 [37-96] 65 [37 - 102] 0.3
Respiratory autonomy (d) 40 [4 - 94] 37 [0 - 88] 37.5 [0 -94] 0.2
Severe cerebral lesions 4 (19 %) 0 (0%) 4 (8 %) 0.02
Post natal steroid therapy 3 (14 %) 3 (11 %) 6 (12 %) 0.7
Retinopathy 2 (9 %) 3 (11 %) 5 (10 %) 0.8
Nosocomial infection 10 (48 %) 6 (22 %) 16 (33 %) 0.06
Necrotizing enterocolitis 3 (14 %) 2 (7 %) 5 (10.4) 0.4
* n (%); **median [Min-Max].
Table 2 Hematological data of the newborns with and without erythropoietin therapy
Treated group (n=21) Non treated group (n=27) Total (n=48) p
Volume of phlebotomy losses (ml/kg)* 16.8 [6.9 - 49.4] 14.5 [7.6 - 50.0] 15.1 [6.9 - 50.0] 0.7
Start of iron supplementation (age in days) 22 [13 - 51] 20 [5 - 38] 20.5 [5 - 51] 0.5
Transfusions before day 15 of life
Nb of infants transfused <D15** 9 (43 %) 5 (18 %) 14 (29 %) 0.07
Transfusions per infant <D15 0 [0 - 2] 0 [0 - 1] 0 [0 - 2] 0.9
Transfusion after day 15 of life
Nb of infants transfused ≥D15 7 (33 %) 9 (33 %) 16 (33 %) 1.00
Transfusions per infant ≥D15 0 [0 - 3] 0 [0-2] 0 [0 - 3] 0.6
Day 0 of life
Haemoglobin (g/dL) 15.2 [11.9-17.7] 15.9 [13.1-18.9] 15.5 [11.9-18.9] 0.2
2-3 wks
Haemoglobin (g/dl) 11.4 [8.1-14.8] 11.3 [6.7-12.9] 11 [6.7 - 14.8] 0.9
Age at sampling (d) 15 [14 - 21] 16 [14 - 21] 16 [14 - 21] 0.3
1 month of life
Haemoglobin (g/dl) 9.9 [8.4 -12.8] 10.0 [8.1- 12.9] 10 [8.1 - 12.9] 0.7
Age at sampling (d) 34 [29- 39] 32 [28- 39 ] 33 [28 - 39] 0.4
Discharge
Haemoglobin (g/dl) 10.4 [7.7 -12.4] 9.6 [8.4- 11.7] 9.6 [7.7 - 12.4] 0.3
n=13 n= 21 n=34
Age at sampling (d) 72 [43 - 99] 65 [46 - 93] 67 [43 - 99] 0.9
*median [Min-Max], ** n (%).
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Table 3 Influence of different factors on the need for
transfusion after 15 days of life
Variables Odds ratio 95% IC p
Gestational age at birth* 0.18 0.03-0.96 0.044
Intrauterine growth retardation 0.63 0.06-6.94 0.704
Gender (boy) 0.22 0.03-1.92 0.171
Volume of phlebotomy losses (mL/kg/d) 1.17 1.01-1.36 0.032
Treatment with erythropoietin 0.15 0.01-1.60 0.118
*The variable “gestational age at birth” was divided into the following classes:
<28 weeks, 28–29.9 weeks and 30–32 weeks.
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limit the number of infants transfused [2,3,5,12,13,24-30].
Based on the results of the literature, the French author-
ities issued guidelines questioning the need for EPO when
policies of restrictive transfusion criteria and a single donor
for repeated transfusions were applied [18].
Cell transfusion practices vary widely among practicing
neonatologists throughout the world [31]. Some studies
have shown that it is equally efficacious to employ a con-
servative transfusion protocol as to use early administra-
tion of EPO in premature infants of gestational age <30
weeks and/or birth weight <1500 g [24]. Others have dem-
onstrated an absence of any increase in mortality, duration
of hospitalization or occurrence of severe cerebral lesions,
apnea, retinopathy or bronchopulmonary dysplasia when
a conservative transfusion policy was employed [23,24].
However, although most authors have a tendency to use a
restrictive guidelines, the use of a restrictive or liberal
guidelines for red blood cell transfusion in preterm
infants, remain a controversial issue since their impactTable 4 Comparison of the volumes of phlebotomy losses in
References Year of publication Population studie
[5] 1993 27-33 wks
[2] 1993 < 33 wks
[3] 1994 750 - 1500 g
[36] 1997 ≤ 1500 g
[25] 1999 ≤ 32 wks
[26] 2000 < 32 SA and < 1250
[12] 2001 < 1000 g
1000–1250 g
[13] 2002 < 1000 g
[37] 2005 500 - 1000 g
[27] 2006 450 - 800 g
[24] 2006 < 30 wks or > 1500
[28] 2008 1000 - 1750 g and 28–3
[29] 2011 ≤ 1250 g and < 30 w
[6] 2013 500 – 1250 g
Present study <32 weeks and < 150on the neurosensorial and neurocognitive development
through infanthood and childhood is inconsistent
[26,32-35].
Our study shows that the volume of phlebotomy losses
is an independent factor significantly associated with the
need for late transfusion. Previous study have shown that
considerable phlebotomy losses are a risk factor associated
with the need for early transfusion in very preterm infants.
For example, it has been shown in infants not treated with
EPO, that the volume of blood losses during the first 7
days of life is a significant predictive factor for transfusion
over the first 7 days of life [36]. In a randomized controlled
trial testing a bedside blood analyzer, blood transfusions
administered to extremely low birth weight infants were
reduced by decreasing laboratory phlebotomy losses [37].
Our study adds to the literature by the fact that the volume
of phlebotomy losses is associated with the need for late
transfusion even if an effective blood sparing protocol is
applied. Indeed, our blood saving protocol is one of the
most efficient published to date since the volume of
phlebotomy losses during the first month of life was ~0.5
mL/kg/d in the two groups, which is a figure lower than
most of the values published (Table 4).
Our work presents several limitations. The retrospective
nature of the data collection imposes the limits inherent
to this type of study. However, the number of infants
transfused, the number of transfusions per infant and the
evolution of hemoglobin levels were unlikely to be affected
by their retrospective retrieval due to the existence of a
transfusion record in all the medical files and the electronic
recording of all biological results. On the other hand, there
is probably some uncertainty concerning the actual volumepreterm infants published in the literature













4 wks 40 0.8
ks 30 0.4
99 0.8
0 g 47 0.5
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although it is unlikely that the error induced would be
different between the two groups since the sampling
procedure did not change during the period of the study.
We could not assess the impact of the discontinuation of
EPO therapy on reticulocytosis as the number of infants
in whom this test was performed was too low, even
though it is recognized that this parameter is affected by
EPO [9,38]. The small number of patients in each group is
a weakness of the study and makes the demonstration of
the direct effect of the intervention (arrest of EPO) more
uncertain. We could nevertheless calculate that the number
of children included in the study allowed one to test the
hypothesis of a doubling of the risk of transfusion with a
power of 80% and an alpha risk of 0.05. Our work shows
that a gestational age of <28 weeks is an independent risk
factor for late transfusions and hence it would be ap-
propriate to specifically test the effects of EPO in this
subgroup of extremely premature infants. Finally, our
study was not able to determine the role of delayed cord
clamping on the need for late blood transfusion since
the procedure was not used in our perinatal department
during the study periods.
Conclusion
In conclusion, this study showed that the number of late
transfusions had not increased significantly one year
after the discontinuation of EPO. In units where policies
of conservative transfusion and single donors are applied,
it would seem reasonable to discontinue the use of early
EPO treatment for very preterm infants for which the ad-
ministration procedure is painful, the large scale clinical
efficacy is modest and the absence of side effects does not
appear to be fully established. In the area of conservative
transfusion policy and blood sparing, we found that
phlebotomy losses remained an important risk factor
for late transfusion.
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